Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma

Fineline Cube Feb 4, 2024

Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the...

Company

Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels

Fineline Cube Feb 4, 2024

Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the...

Company Drug

Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products

Fineline Cube Feb 4, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...

Company Deals

Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion

Fineline Cube Feb 2, 2024

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S....

Company Drug

Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients

Fineline Cube Feb 2, 2024

Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...

Company Deals

Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development

Fineline Cube Feb 2, 2024

Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...

Company

Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal

Fineline Cube Feb 2, 2024

Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Aims for Singapore Approval in Nasopharyngeal Carcinoma

Fineline Cube Feb 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company

Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales

Fineline Cube Feb 2, 2024

Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...

Company

Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus

Fineline Cube Feb 2, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the...

Company Drug

Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts

Fineline Cube Feb 2, 2024

Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...

Company

Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand

Fineline Cube Feb 2, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...

Company Deals

Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment

Fineline Cube Feb 2, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...

Policy / Regulatory

NHSA Launches Service Specifications for Medical Procurement Platform

Fineline Cube Feb 2, 2024

The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement...

Policy / Regulatory

China’s NHC Unveils 2024 Goals for Medical Quality and Safety Improvement

Fineline Cube Feb 2, 2024

The National Health Commission (NHC) has released the “2024 National Medical Quality and Safety Improvement...

Company

WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility

Fineline Cube Feb 1, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Deals

HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development

Fineline Cube Feb 1, 2024

HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...

Company Deals

Novartis and Fudan University Shanghai Cancer Center Renew Partnership to Drive Precision Cancer Treatments

Fineline Cube Feb 1, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical colossus, has renewed its memorandum of understanding with Fudan...

Company Deals

Rebecca Tech Secures USD 10 Million in Series A++ Funding to Expand Micro RF Technology Globally

Fineline Cube Feb 1, 2024

Rebecca Tech LLC, a Hangzhou-based manufacturer specializing in microelectromechanical RF (radiofrequency) technology, has announced the...

Company

Jiangsu Hengrui Receives Chinese Approval for First Domestic Category 1 Opioid Analgesic for Postoperative Pain

Fineline Cube Feb 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has proclaimed the receipt of marketing approval in...

Posts pagination

1 … 412 413 414 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.